Pfizer/BioNTech Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the Pfizer/BioNTech Covid-19 vaccine (BNT162b2):
- FDA EUA document for Pfizier/BioNTech
- FDA Briefing Document with data for Pfizer/BioNTech Covid-19 vaccine
- Pfizer/BioNTech Fact Sheet for Health Providers
- Pfizer/BioNTech Fact Sheet for Recipients and Caregivers
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (Aug 2020)
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (Sept 2020)
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (preprint, July 2020)
- Here are all other planned or in-progress trials for the Pfizer/BioNTech vaccine at ClinicalTrials-gov.
Moderna Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the Moderna Covid-19 vaccine (mRNA-1273):
- FDA EUA document for Moderna Covid-19 vaccine
- FDA Briefing Document Addendum for Moderna Covid-19 vaccine
- Moderna Fact Sheet for Health Providers
- Moderna Fact Sheet for Recipients and Caregivers
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- Here are all other planned or in-progress trials for the Pfizer/BioNTech vaccine at ClinicalTrials-gov.
Johnson & Johnson Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the Johnson & Johnson Covid-19 vaccine (BNT162b2):
- FDA Briefing Document for Johnson & Johnson vaccine
- Johnson & Johnson Fact Sheet for Health Providers
- Johnson & Johnson Fact Sheet for Recipients and Caregivers
- Phase 1: Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
- Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (preprint)
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- Here are the ClinicalTrials-gov links for the phase 1/2, primary phase 3, additional phase 3, and a phase 3 trial with an adjuvant.
- Here are all other planned or in-progress trials for the Johnson & Johnson vaccine at ClinicalTrials-gov.
AstraZeneca/Oxford Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the AstraZeneca/Oxford Covid-19 vaccine (ChAdOx1/AZD1222) – not currently authorized in the US:
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 trial
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
- Here are all other planned or in-progress trials for the AstraZeneca/Oxford vaccine at ClinicalTrials-gov.
The following studies investigate how well the COVID-19 vaccines prevent infection — when a virus enters the body’s cells and begins replicating—aside from simply preventing disease, when symptoms actually occur. While not necessarily exhaustive, these are the majority of studies available on infection prevention of the vaccines through April 20, 2021.
- Moderna mRNA-1273 Sponsor Briefing Document Addendum, Vaccines and Related Biological Products Advisory Committee, 17 December 2020: Data to Support Efficacy Against Asymptomatic Infection.
- Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19, FDA Briefing Document, pg. 35.
- Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2 (preprint). doi:10.1101/2021.02.08.21251329.
- FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system (preprint). Doi:10.1101/2021.02.15.21251623.
- Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)(preprint). Doi:10.2139/ssrn.3790399
- Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients, Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7.
- Pfizer press release only: Real-world evidence confirms high effectiveness of Pfizer/BioNTech Covid-19 vaccine and profound public health impact of vaccination one year after pandemic declared.
- Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine, Nat Med. 2021 Mar 29. doi: 10.1038/s41591-021-01316-7.
- Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening, Clin Infect Dis. 2021 Mar 10;ciab229. doi: 10.1093/cid/ciab229.
- SARS-CoV-2 Infection after Vaccination in Health Care Workers in California, N Engl J Med. 2021 Mar 23;NEJMc2101927. doi: 10.1056/NEJMc2101927.
- Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center, N Engl J Med. 2021 Mar 23;NEJMc2102153. doi: 10.1056/NEJMc2102153.
- BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers, N Engl J Med. 2021 Mar 23;NEJMc2101951. doi: 10.1056/NEJMc2101951.
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765.
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021, MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3.
Each of these sites are tracking clinical trials related to COVID-19, including both vaccines and therapeutic drugs and other interventions. It’s unclear whether any of them are 100% complete, and some may have inadvertent bias depending on who is collecting the information and how, but having all of them will mean it will be hard to miss a trial.
The Centre for Evidence-Based Medicine from the University of Oxford has a page with a holistic analysis of 382 registered trials and then a Trials Tracker page with a spreadsheet containing more than 700 entries.
A collaboration of Cytel Inc. and the Bill & Melinda Gates Foundation has produced a Global Coronavirus COVID-19 Clinical Trial Tracker that includes a map of where the trials are taking place. The interactive interface allows users to filter according to treatment and country, and a spreadsheet at the bottom allows sorting by multiple fields, including the trial’s status and disease severity.
Though less easier to search visually, the Regulatory Affairs Professionals Society is updating their COVID-19 Therapeutics Tracker weekly, so it might be a good place to get a sense on an ongoing basis of what’s happening.
TranspariMed offers a guide to 500 clinical trials on COVID-19 interventions
Cell Trials Data has a page with a downloadable Excel spreadsheet file for all COVID-19 clinical trials current through the date on their site.
The Milken Institute has a PDF version of their COVID-19 Treatment and Vaccine Tracker. The lower right corner of each page notes when the tracker was last updated.